Steven P. Coen sold $2,576 of DNA
See remarks at Ginkgo Bioworks Holdings, Inc.. 324 shares at an average of $7.95, traded Apr 17, 2026, filed Apr 20, 2026.
Score components
- +15RoleOfficer
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.3%, 3m -5.4%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-026038, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | MOption exercise Class A Common Stock | +587 | - | - | 50,436 | Apr 20, 2026 |
| Apr 16, 2026 | MOption exercise Class A Common Stock | +156 | - | - | 50,592 | Apr 20, 2026 |
| Apr 17, 2026 | SOpen-market sale Class A Common Stock | -324 | $7.95 | $2,576 | 50,268 | Apr 20, 2026 |
| Apr 16, 2026 | MOption exercise Restricted Stock Unitsderivative | -587 | - | - | 7,644 | Apr 20, 2026 |
| Apr 16, 2026 | MOption exercise Restricted Stock Unitsderivative | -156 | - | - | 3,599 | Apr 20, 2026 |
Related signals
Other insiders at Ginkgo Bioworks Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $36k 2,403 shares | -5% | |
| 26Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Christian O Henry director | $35k 5,000 shares | -21% | |
| 0Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $2,302 330 shares | -1% | |
| 0Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $5,943 752 shares | -1% | |
| 0Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $2,559 307 shares | -1% | |
| 37Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $213k 33,171 shares | -40% | |
| 39Weak | Ginkgo Bioworks Holdings, Inc. | Barry Canton owner | $802k 124,727 shares | -22% | |
| 42Moderate | Ginkgo Bioworks Holdings, Inc. | Reshma P. Shetty See remarks | $802k 124,727 shares | -22% | |
| 24Weak | Ginkgo Bioworks Holdings, Inc. | Barry Canton owner | $175k 26,271 shares | -7% | |
| 50Moderate | Ginkgo Bioworks Holdings, Inc. | Jason R Kelly See remarks | $1.4M 206,782 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.